ALKS Share Price

Open 50.42 Change Price %
High 50.64 1 Day 0.03 0.06
Low 50.04 1 Week -1.65 -3.17
Close 50.37 1 Month 0.16 0.32
Volume 385423 1 Year 0.79 1.59
52 Week High 63.40
52 Week Low 41.93
ALKS Important Levels
Resistance 2 50.93
Resistance 1 50.70
Pivot 50.35
Support 1 50.04
Support 2 49.81
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Alkermes plc (NASDAQ: ALKS)

ALKS Technical Analysis 4
As on 22nd Sep 2017 ALKS Share Price closed @ 50.37 and we RECOMMEND Sell for LONG-TERM with Stoploss of 56.11 & Strong Sell for SHORT-TERM with Stoploss of 53.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALKS Target for September
1st Target up-side 54.15
2nd Target up-side 56.51
3rd Target up-side 58.87
1st Target down-side 47.41
2nd Target down-side 45.05
3rd Target down-side 42.69
ALKS Other Details
Segment EQ
Market Capital 2719078400.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.alkermes.com
ALKS Address
ALKS
Connaught House
1 Burlington Road
Dublin, 4
Ireland
Phone: 353 1 772 8000
ALKS Latest News
Interactive Technical Analysis Chart Alkermes plc ( ALKS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alkermes plc
ALKS Business Profile
Alkermes Public Limited Company, incorporated on May 4, 2011, is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures RISPERDAL CONSTA, VIVITROL and polymer for BYDUREON in its Wilmington, Ohio facility. The Company operates PERDAL CONSTA lines and one VIVITROL line at commercial scale. The Company manufactures AMPYRA/FAMPYRA, RAPAMUNE and other products in its Athlone, Ireland facility. It manufactures FOCALIN XR, RITALIN LA, AVINZA, VERAPAMIL and other products in its Gainesville, Georgia facility. The Company’s RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate its technologies. RISPERDAL CONSTA uses its polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is manufactured by the Company and is marketed and sold by Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (Janssen) around the globe. INVEGA SUSTENNA uses its nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration.